REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the ...

COVID Landscape and Vaccine Challenges - COVID vaccines may face durability issues due to the nature of coronavirus immunity[9, 10] - A CDC survey in June-July 2024 indicated that 20% of adults avoided COVID vaccines due to concerns about serious/unknown side effects[13] - Americans have avoided COVID vaccines due to safety fears and mistrust[12] Invivyd's Antibody Approach - Invivyd is developing best-in-class antibody protection and treatment of viral threats[5] - Invivyd's monoclonal antibodies can be engineered for consistent high activity, unlike vaccines[19] - Pemivibart's target epitope has remained relatively unchanged over the past 3 years[22, 23] - VYD2311 is a minimally evolved molecular engineered antibody designed to improve performance[24] REVOLUTION Clinical Program - VYD2311 Phase 1/2 study showed attractive safety at high doses, up to 4500 mg IV[35, 38] - The DECLARATION Phase 3 clinical trial will evaluate prevention of symptomatic COVID at three months[45] - The company aims for a 70%-90% reduction in symptomatic COVID with a 250 mg single dose IM of VYD2311 versus placebo over 3 months[47] Commercial Landscape - Approximately 342 million of the US population is 12+[74] - In the 24-25 flu season, 147 million flu vaccine doses were administered[75] - 36% was the 2023-2024 vaccine dose, ≥7 days 18 and over vaccine efficacy (VE) reduction in hospitalization estimate from CDC[73]

Core Points - Allogene Therapeutics will report its third quarter 2025 financial results and provide a business update on November 6, 2025, after market close [1] - A live audio webcast and conference call will follow the announcement at 2:00 p.m. PT/5:00 p.m. ET [1] - The listen-only webcast will be available on the company's website for approximately 30 days [2] Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [4] - The company aims to deliver "off-the-shelf" CAR T cell product candidates that are readily available on-demand, more reliably, and at greater scale to a larger patient population [4] - The management team has significant experience in cell therapy, which supports the company's development efforts [4] Conference Call Information - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]

Group 1 - The core viewpoint emphasizes the critical role of the capital market in supporting technological innovation and industrial integration during China's economic transformation [2][3] - The capital market serves as a key hub for technology innovation, effectively matching the high-risk, high-reward characteristics of tech enterprises with unique support models [2][3] - The multi-tiered capital market effectively guides social capital towards technology innovation, enhancing the proportion of direct financing [3][4] Group 2 - Various market segments, including the Shanghai and Shenzhen main boards, Sci-Tech Innovation Board, and others, develop in a complementary manner to support different types of innovative enterprises [4] - The Sci-Tech Innovation Board has attracted numerous high-growth potential "hard tech" companies by implementing flexible listing standards [5][6] - The establishment of the National Venture Capital Guidance Fund aims to leverage fiscal funds to attract nearly 1 trillion yuan in social capital, focusing on cutting-edge technology fields [7][8] Group 3 - The securities industry is enhancing its functional positioning to support high-quality development in technology innovation through professional services and financial technology [10][12] - Securities firms act as "gatekeepers," connecting tech enterprises with the capital market and ensuring accurate information disclosure [11][12] - The private equity investment funds play a crucial role in promoting technology innovation by directing capital towards early-stage and growth-stage "hard tech" enterprises [12][13] Group 4 - Securities companies are deepening industry research to provide valuable insights and enhance the understanding of technology innovation within the capital market [13][14] - The integration of technology into business operations is improving service efficiency and risk management capabilities within securities firms [14]

SUNNYVALE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled at University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial. “CardiAMP cell therapy has shown evidence of benefit for ischemic heart failure patients with elevated markers of heart stress, despite being on opt ...

Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy platforms PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the National Cancer Institute (NCI) will presen ...

HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only ...

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company’s oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia. Details of the presentation are as follows: Abstract Title: O ...

Financial Performance - Q3 2025 net revenues reached $12.9 million, a 44% increase compared to $9.0 million in Q3 2024 [12] - Cash on hand remains strong at $1.3 billion, intended for investment in U S launches and pipeline development [10, 12, 15] - Net loss for Q3 2025 was $103.4 million, compared to a net income of $947.9 million in Q3 2024 [15] PYRUKYND® Commercial Progress - PYRUKYND net sales were $12.9 million in Q3 2025, compared to $12.5 million in Q2 2025 and $9.0 million in Q3 2024 [15, 20] - In the U S, 262 unique PK deficiency patients have completed prescription enrollment forms since launch [20] - There are 149 net patients on PYRUKYND treatment in the U S, including new prescriptions and treatment continuations [20] - PYRUKYND has been prescribed by 227 unique prescribers in the U S [20] Regulatory and Pipeline Advancements - PYRUKYND received SFDA approval in Saudi Arabia for thalassemia [12, 27, 28] - A positive CHMP opinion in Europe was received for PYRUKYND in thalassemia [12, 27, 28] - Enrollment is complete in the tebapivat Phase 2b trial for lower-risk MDS, with top-line data anticipated in early 2026 [12, 27]

Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ETPRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and confe ...